New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles

Nelly Mezzaroba, Sonia Zorzet, Erika Secco, Stefania Biffi, Claudio Tripodo, Marco Calvaruso, Ramiro Mendoza-Maldonado, Sara Capolla, Marilena Granzotto, Ruben Spretz, Gustavo Larsen, Sandra Noriega, Marianna Lucafò, Eduardo Mansilla, Chiara Garrovo, Gustavo H. Marín, Gabriele Baj, Valter Gattei, Gabriele Pozzato, Luis NúñezPaolo Macor

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Current B-cell disorder treatments take advantage of dose-intensive chemotherapy regimens and immunotherapy via use of monoclonal antibodies. Unfortunately, they may lead to insufficient tumor distribution of therapeutic agents, and often cause adverse effects on patients. In this contribution, we propose a novel therapeutic approach in which relatively high doses of Hydroxychloroquine and Chlorambucil were loaded into biodegradable nanoparticles coated with an anti-CD20 antibody. We demonstrate their ability to effectively target and internalize in tumor B-cells. Moreover, these nanoparticles were able to kill not only p53 mutated/deleted lymphoma cell lines expressing a low amount of CD20, but also circulating primary cells purified from chronic lymphocitic leukemia patients. Their safety was demonstrated in healthy mice, and their therapeutic effects in a new model of Burkitt's lymphoma. The latter serves as a prototype of an aggressive lympho-proliferative disease. In vitro and in vivo data showed the ability of anti-CD20 nanoparticles loaded with Hydroxychloroquine and Chlorambucil to increase tumor cell killing in comparison to free cytotoxic agents or Rituximab. These results shed light on the potential of anti-CD20 nanoparticles carrying Hydroxychloroquine and Chlorambucil for controlling a disseminated model of aggressive lymphoma, and lend credence to the idea of adopting this therapeutic approach for the treatment of B-cell disorders.

Original languageEnglish (US)
Article numbere74216
JournalPloS one
Volume8
Issue number9
DOIs
StatePublished - Sep 30 2013

Fingerprint

Hydroxychloroquine
Chlorambucil
nanoparticles
Nanoparticles
B-lymphocytes
B-Lymphocytes
lymphoma
Cells
therapeutics
Tumors
Neoplasms
Lymphoma
biodegradability
neoplasms
immunotherapy
Therapeutics
dosage
leukemia
prototypes
Chemotherapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles. / Mezzaroba, Nelly; Zorzet, Sonia; Secco, Erika; Biffi, Stefania; Tripodo, Claudio; Calvaruso, Marco; Mendoza-Maldonado, Ramiro; Capolla, Sara; Granzotto, Marilena; Spretz, Ruben; Larsen, Gustavo; Noriega, Sandra; Lucafò, Marianna; Mansilla, Eduardo; Garrovo, Chiara; Marín, Gustavo H.; Baj, Gabriele; Gattei, Valter; Pozzato, Gabriele; Núñez, Luis; Macor, Paolo.

In: PloS one, Vol. 8, No. 9, e74216, 30.09.2013.

Research output: Contribution to journalArticle

Mezzaroba, N, Zorzet, S, Secco, E, Biffi, S, Tripodo, C, Calvaruso, M, Mendoza-Maldonado, R, Capolla, S, Granzotto, M, Spretz, R, Larsen, G, Noriega, S, Lucafò, M, Mansilla, E, Garrovo, C, Marín, GH, Baj, G, Gattei, V, Pozzato, G, Núñez, L & Macor, P 2013, 'New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles', PloS one, vol. 8, no. 9, e74216. https://doi.org/10.1371/journal.pone.0074216
Mezzaroba, Nelly ; Zorzet, Sonia ; Secco, Erika ; Biffi, Stefania ; Tripodo, Claudio ; Calvaruso, Marco ; Mendoza-Maldonado, Ramiro ; Capolla, Sara ; Granzotto, Marilena ; Spretz, Ruben ; Larsen, Gustavo ; Noriega, Sandra ; Lucafò, Marianna ; Mansilla, Eduardo ; Garrovo, Chiara ; Marín, Gustavo H. ; Baj, Gabriele ; Gattei, Valter ; Pozzato, Gabriele ; Núñez, Luis ; Macor, Paolo. / New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles. In: PloS one. 2013 ; Vol. 8, No. 9.
@article{16f809ace52d43a2a42896d79cd4a263,
title = "New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles",
abstract = "Current B-cell disorder treatments take advantage of dose-intensive chemotherapy regimens and immunotherapy via use of monoclonal antibodies. Unfortunately, they may lead to insufficient tumor distribution of therapeutic agents, and often cause adverse effects on patients. In this contribution, we propose a novel therapeutic approach in which relatively high doses of Hydroxychloroquine and Chlorambucil were loaded into biodegradable nanoparticles coated with an anti-CD20 antibody. We demonstrate their ability to effectively target and internalize in tumor B-cells. Moreover, these nanoparticles were able to kill not only p53 mutated/deleted lymphoma cell lines expressing a low amount of CD20, but also circulating primary cells purified from chronic lymphocitic leukemia patients. Their safety was demonstrated in healthy mice, and their therapeutic effects in a new model of Burkitt's lymphoma. The latter serves as a prototype of an aggressive lympho-proliferative disease. In vitro and in vivo data showed the ability of anti-CD20 nanoparticles loaded with Hydroxychloroquine and Chlorambucil to increase tumor cell killing in comparison to free cytotoxic agents or Rituximab. These results shed light on the potential of anti-CD20 nanoparticles carrying Hydroxychloroquine and Chlorambucil for controlling a disseminated model of aggressive lymphoma, and lend credence to the idea of adopting this therapeutic approach for the treatment of B-cell disorders.",
author = "Nelly Mezzaroba and Sonia Zorzet and Erika Secco and Stefania Biffi and Claudio Tripodo and Marco Calvaruso and Ramiro Mendoza-Maldonado and Sara Capolla and Marilena Granzotto and Ruben Spretz and Gustavo Larsen and Sandra Noriega and Marianna Lucaf{\`o} and Eduardo Mansilla and Chiara Garrovo and Mar{\'i}n, {Gustavo H.} and Gabriele Baj and Valter Gattei and Gabriele Pozzato and Luis N{\'u}{\~n}ez and Paolo Macor",
year = "2013",
month = "9",
day = "30",
doi = "10.1371/journal.pone.0074216",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles

AU - Mezzaroba, Nelly

AU - Zorzet, Sonia

AU - Secco, Erika

AU - Biffi, Stefania

AU - Tripodo, Claudio

AU - Calvaruso, Marco

AU - Mendoza-Maldonado, Ramiro

AU - Capolla, Sara

AU - Granzotto, Marilena

AU - Spretz, Ruben

AU - Larsen, Gustavo

AU - Noriega, Sandra

AU - Lucafò, Marianna

AU - Mansilla, Eduardo

AU - Garrovo, Chiara

AU - Marín, Gustavo H.

AU - Baj, Gabriele

AU - Gattei, Valter

AU - Pozzato, Gabriele

AU - Núñez, Luis

AU - Macor, Paolo

PY - 2013/9/30

Y1 - 2013/9/30

N2 - Current B-cell disorder treatments take advantage of dose-intensive chemotherapy regimens and immunotherapy via use of monoclonal antibodies. Unfortunately, they may lead to insufficient tumor distribution of therapeutic agents, and often cause adverse effects on patients. In this contribution, we propose a novel therapeutic approach in which relatively high doses of Hydroxychloroquine and Chlorambucil were loaded into biodegradable nanoparticles coated with an anti-CD20 antibody. We demonstrate their ability to effectively target and internalize in tumor B-cells. Moreover, these nanoparticles were able to kill not only p53 mutated/deleted lymphoma cell lines expressing a low amount of CD20, but also circulating primary cells purified from chronic lymphocitic leukemia patients. Their safety was demonstrated in healthy mice, and their therapeutic effects in a new model of Burkitt's lymphoma. The latter serves as a prototype of an aggressive lympho-proliferative disease. In vitro and in vivo data showed the ability of anti-CD20 nanoparticles loaded with Hydroxychloroquine and Chlorambucil to increase tumor cell killing in comparison to free cytotoxic agents or Rituximab. These results shed light on the potential of anti-CD20 nanoparticles carrying Hydroxychloroquine and Chlorambucil for controlling a disseminated model of aggressive lymphoma, and lend credence to the idea of adopting this therapeutic approach for the treatment of B-cell disorders.

AB - Current B-cell disorder treatments take advantage of dose-intensive chemotherapy regimens and immunotherapy via use of monoclonal antibodies. Unfortunately, they may lead to insufficient tumor distribution of therapeutic agents, and often cause adverse effects on patients. In this contribution, we propose a novel therapeutic approach in which relatively high doses of Hydroxychloroquine and Chlorambucil were loaded into biodegradable nanoparticles coated with an anti-CD20 antibody. We demonstrate their ability to effectively target and internalize in tumor B-cells. Moreover, these nanoparticles were able to kill not only p53 mutated/deleted lymphoma cell lines expressing a low amount of CD20, but also circulating primary cells purified from chronic lymphocitic leukemia patients. Their safety was demonstrated in healthy mice, and their therapeutic effects in a new model of Burkitt's lymphoma. The latter serves as a prototype of an aggressive lympho-proliferative disease. In vitro and in vivo data showed the ability of anti-CD20 nanoparticles loaded with Hydroxychloroquine and Chlorambucil to increase tumor cell killing in comparison to free cytotoxic agents or Rituximab. These results shed light on the potential of anti-CD20 nanoparticles carrying Hydroxychloroquine and Chlorambucil for controlling a disseminated model of aggressive lymphoma, and lend credence to the idea of adopting this therapeutic approach for the treatment of B-cell disorders.

UR - http://www.scopus.com/inward/record.url?scp=84884741190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884741190&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0074216

DO - 10.1371/journal.pone.0074216

M3 - Article

C2 - 24098639

AN - SCOPUS:84884741190

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e74216

ER -